Capital Advisors Inc. OK Purchases 49,060 Shares of Medtronic PLC $MDT

Capital Advisors Inc. OK raised its position in shares of Medtronic PLC (NYSE:MDT) by 8.3% during the 4th quarter, Holdings Channel reports. The fund owned 639,288 shares of the medical technology company’s stock after purchasing an additional 49,060 shares during the period. Capital Advisors Inc. OK’s holdings in Medtronic were worth $61,410,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares during the last quarter. VestGen Advisors LLC lifted its holdings in shares of Medtronic by 22.3% in the 2nd quarter. VestGen Advisors LLC now owns 3,233 shares of the medical technology company’s stock valued at $282,000 after acquiring an additional 589 shares during the last quarter. Smith Moore & CO. grew its position in Medtronic by 2.4% in the second quarter. Smith Moore & CO. now owns 12,636 shares of the medical technology company’s stock worth $1,101,000 after acquiring an additional 295 shares in the last quarter. Finally, Van Hulzen Asset Management LLC increased its stake in Medtronic by 26.2% during the second quarter. Van Hulzen Asset Management LLC now owns 6,387 shares of the medical technology company’s stock worth $557,000 after acquiring an additional 1,326 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MDT shares. Wells Fargo & Company started coverage on Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective on the stock. CICC Research initiated coverage on Medtronic in a research report on Friday, January 30th. They set an “outperform” rating on the stock. Barclays restated an “overweight” rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, February 18th. Daiwa Securities Group lowered their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Stock Up 1.0%

Shares of NYSE:MDT opened at $86.57 on Wednesday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The business has a 50 day simple moving average of $95.34 and a two-hundred day simple moving average of $96.41. The firm has a market capitalization of $111.15 billion, a PE ratio of 24.12, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).